Wednesday, 15 May

08:00 – 17:30

Registration Open
Saal MARITIM & Lobby Empore

09:00 – 09:05

Welcome and Introduction
Alte Stuttgarter Reithalle

Committee Member: Falk Klar, PhD, Parenteral Drug Association

09:05 – 09:15

Welcome from the Co-Chairs
Alte Stuttgarter Reithalle

Co-Chair: Simone Biel, PhD, Senior Regulatory Consultant, Merck
Co-Chair: Darren Beckett, Sr. Training and R&D Manager, Fedegari Technologies Inc

09:15 – 10:45

Opening Plenary Part I: Advancing Aseptic Manufacturing for Safe Medicines - Lessons Learned and Path Forward
Alte Stuttgarter Reithalle

Through insightful keynote presentations, interactive discussions, and case studies, participants will explore the challenges and achievements in EU GMP Annex 1 implementation. Join us for this thought-provoking session as we collectively reflect on the progress made thus far, identify areas for improvement, and lay the groundwork for a harmonized approach to aseptic manufacturing that ensures the continued delivery of safe medicines to patients worldwide.

Moderator: Simone Biel, PhD, Senior Regulatory Consultant, Merck

09:15 – 09:45


Presenter: Hussain Jafri, PhD, Executive Director, World Patients Alliance

09:45 – 10:15

Fit for Future: Sterile Manufacture? A Personal View on Revised EU GMP Annex 1

Regulatory Presenter: Daniel Mueller, PhD, Head of GMDP-Inspectorate, Regierungspraesidium Tuebingen, Germany

10:15 – 10:45

Implementation of EU GMP Annex 1 – Inspection Experiences and Expectations

Regulatory Presenter: Christina Meissner, AGES - Austrian Agency for Health and Food Safety
10:45 – 11:15

Networking Coffee Break, Poster Session & Exhibition
Saal MARITIM & Lobby Empore

11:15 – 12:45

Opening Plenary Part II: Advancing Aseptic Manufacturing for Safe Medicines - Lessons Learned and Path Forward
Alte Stuttgarter Reithalle

Through insightful keynote presentations, interactive discussions, and case studies, participants will explore the challenges and achievements in Annex 1 implementation. Join us for this thought-provoking session as we collectively reflect on the progress made thus far, identify areas for improvement, and lay the groundwork for a harmonized approach to aseptic manufacturing that ensures the continued delivery of safe medicines to patients worldwide.

**Moderator:** Simone Biel, PhD, Senior Regulatory Consultant, Merck

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
</table>
| 11:15 | The Evolution of the Contamination Control Strategy from Concept/Conversion to Continuous Improvement  
**Presenter:** Tracy Moore, Director, TM Pharma Group Ltd |
| 11:35 | EU GMP Annex 1 Implementation: A Case Study of the Sterile Production at F. Hoffmann-La Roche Ltd.  
**Presenter:** Tarik Cheema, PhD, End to End Contamination Control Manager, F. Hoffmann-La Roche AG |
| 11:55 | Interactive Questionnaire Session                                                |
| 12:00 | Plenary Discussion                                                               |

**Moderator:** Simone Biel, PhD, Senior Regulatory Consultant, Merck

**Moderator:** Darren Beckett, Sr. Training and R&D Manager, Fedegari Technologies Inc

**Panelist:** Hussain Jafri, PhD, Executive Director, World Patients Alliance

**Panelist:** Tarik Cheema, PhD, End to End Contamination Control Manager, F. Hoffmann-La Roche AG

**Panelist:** Tracy Moore, Director, TM Pharma Group Ltd

**Panelist:** Christina Meissner, AGES - Austrian Agency for Health and Food Safety

**Panelist:** Daniel Mueller, PhD, Head of GMDP-Inspectorate, Regierungspraesidium Tuebingen, Germany

**Panelist:** Marisa Delbo, PharmD, Consultant, NA

12:45 – 14:00
### Agenda

**PDA Good Aseptic Manufacturing Conference 2024**

**Networking Lunch Break & Exhibition**

Saal MARITIM & Lobby Empore

13:30 – 14:00

**Guided Poster Walk**

Lobby Empore

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 – 14:00</td>
<td>Biodecontamination of Raw Materials in Packaging Production Process</td>
</tr>
<tr>
<td></td>
<td><strong>Poster Presenter:</strong> Andrea Weiss</td>
</tr>
<tr>
<td>13:30 – 14:00</td>
<td>CFD - Computational Fluid Dynamics for Airflow Visualization Studies</td>
</tr>
<tr>
<td></td>
<td><strong>Poster Presenter:</strong> Christian Scarpato, Process Engineering Manager, Merck</td>
</tr>
<tr>
<td>13:30 – 14:00</td>
<td>eBeam Technology – Transfer Technology for Pre-Sterilized RTU Components</td>
</tr>
<tr>
<td></td>
<td><strong>Poster Presenter:</strong> Manfred Holzer, Strategic Product Manager E-Beam Technology, SKAN AG</td>
</tr>
<tr>
<td>13:30 – 14:00</td>
<td>Environmental Monitoring in LIMS</td>
</tr>
<tr>
<td></td>
<td><strong>Poster Presenter:</strong> Julia Wiesner, PhD, Senior Director, Head of QC &amp; QA Systems, Merz Pharma GmbH &amp; Co. KGaA</td>
</tr>
<tr>
<td>13:30 – 14:00</td>
<td>Far UV-C Light - Safe and Effective Decontamination</td>
</tr>
<tr>
<td></td>
<td><strong>Poster Presenter:</strong> Peter Tonning</td>
</tr>
<tr>
<td>13:30 – 14:00</td>
<td>Headspace Analysis as Innovative Method for Media Fill Inspection</td>
</tr>
<tr>
<td></td>
<td><strong>Poster Presenter:</strong> Michael Mettraux, MSc ETH, Development Engineer, WILCO AG</td>
</tr>
<tr>
<td>13:30 – 14:00</td>
<td>Particle Loss in Transport Tubing: How to Address the New Annex 1 Requirement</td>
</tr>
<tr>
<td></td>
<td><strong>Poster Presenter:</strong> Serena Steidl, MD, EMEA Advisory Project Coordinator - Advisory Specialist, Particle Measuring Systems</td>
</tr>
</tbody>
</table>
### Agenda

**PDA Good Aseptic Manufacturing Conference 2024**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13:30 – 14:00 | Rapid Sterility Testing as the Critical and Final Result for Product Release - Design Verification (DV) Data  
**Poster Presenter:** Johannes Oberdörfer, B.Sc, Field Application Scientist, *Rapid Micro Biosystems* |
| 13:30 – 14:00 | Reducing Glove Intervention in Fill & Finish Process  
**Poster Presenter:** Patrick Wieland |
| 13:30 – 14:00 | The Need for High Quality in Primary Packaging  
**Poster Presenter:** Ana Kuschel, PhD, Principal Scientific Affairs, *West Pharmaceutical Services, Inc.*  
**Poster Presenter:** Niamh Bissett |
| 13:30 – 14:00 | Trending and Pattern Recognition for Annex1  
**Poster Presenter:** Susan B. Cleary, B.CS, EMBA, Director Product Development, *Novatek* |
| 13:30 – 14:00 | VHP Uptake of Manufacturing Tubing Used for Aseptic Fill-Finish Processes of Biopharmaceutical Drug Products  
**Poster Presenter:** Dilara Ali, MSc, PhD Student, *ten23 health* |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14:00 – 15:20 | **Session 1, Track A: Impact of EU GMP Annex 1 on Lyophilization**  
**Moderator:** Andrea Salmaso, PharmD, Corporate Regulatory and Scientific Affairs Manager, *Stevanato Group*  
*Alte Stuttgarter Reithalle* |
| 14:00 – 14:25 | Requirements for Lyophilization in the New EU GMP Annex 1  
**Regulatory Presenter:** Marisa Delbo, PharmD, Consultant, *NA* |
| 14:25 – 14:50 | **Session 1, Track A: Impact of EU GMP Annex 1 on Lyophilization**  
**Moderator:** Andrea Salmaso, PharmD, Corporate Regulatory and Scientific Affairs Manager, *Stevanato Group*  
*Alte Stuttgarter Reithalle* |
| 14:00 – 15:20 | **Session 1, Track A: Impact of EU GMP Annex 1 on Lyophilization**  
**Moderator:** Andrea Salmaso, PharmD, Corporate Regulatory and Scientific Affairs Manager, *Stevanato Group*  
*Alte Stuttgarter Reithalle* |
A Better Approach to Aseptic Process Simulation (APS) for Lyophilized Products - APS Approach for Freeze-Drying Process Considering EU GMP Annex 1 Requirements

**Presenter:** Christian Scarpato, Process Engineering Manager, Merck

14:50 – 15:20

Q&A, Discussion

**Moderator:** Andrea Salmaso, PharmD, Corporate Regulatory and Scientific Affairs Manager, Stevanato Group

**Panelist:** Marisa Delbo, PharmD, Consultant, NA

**Panelist:** Christian Scarpato, Process Engineering Manager, Merck

---

14:00 – 15:20

**Session 1, Track B: Sustainability in Aseptic Manufacturing**

Session: **Salon Köln, Bonn, Hamburg**

Sustainability is a core value within the whole industry today and the pharmaceutical industry – aseptic process is not an exception. In this session, we will first give an insight into how design, technology, and innovation will participate in setting up sustainable solutions reducing our global impact on the environment by overviewing big levers e.g. Water for Injection (WFI), Steam generation, HVAC, circular economy (Single use and Take-back program). Then focus will be given to Big Data and Artificial intelligence (AI) to model material impact assessment. While discussing performance and growth, the success of the industry remains that the only way to continue to supply and deliver sustainably is to deliver safety, and compliance in an efficient way.

**Moderator:** Paul Devuyst, Master Bioengineer, Senior Manager Aseptic Technologies, GSK

14:00 – 14:25

From Sustainability Ambitions into Action: What About Aseptic Manufacturing?

**Presenter:** Michael Hell, PhD, Head of Environment / Sustainability Healthcare Operations, Merck Healthcare KGaA

14:25 – 14:50

Can We Have Reliable and Fast Sustainability Impact Assessments? Merging Technology, Innovation, and Sustainability

**Presenter:** Alissa Monk, Sustainability Lead, ten23 health

14:50 – 15:20

Q&A, Discussion

**Moderator:** Paul Devuyst, Master Bioengineer, Senior Manager Aseptic Technologies, GSK

**Panelist:** Michael Hell, PhD, Head of Environment / Sustainability Healthcare Operations, Merck Healthcare KGaA

**Panelist:** Alissa Monk, Sustainability Lead, ten23 health

---

15:20 – 15:50

A Better Approach to Aseptic Process Simulation (APS) for Lyophilized Products - APS Approach for Freeze-Drying Process Considering EU GMP Annex 1 Requirements

**Presenter:** Christian Scarpato, Process Engineering Manager, Merck

14:50 – 15:20

Q&A, Discussion

**Moderator:** Andrea Salmaso, PharmD, Corporate Regulatory and Scientific Affairs Manager, Stevanato Group

**Panelist:** Marisa Delbo, PharmD, Consultant, NA

**Panelist:** Christian Scarpato, Process Engineering Manager, Merck
Session 2, Track A: Filtration and Closed Systems
Alte Stuttgarter Reithalle

At the heart of patient safety, aseptic processing is a critical component of drug product manufacturing, and ensuring the integrity of one’s process is paramount. During this session, we will have two subject matter experts on the subject speak about their experiences around filtration and single-use assembly integrity. They will assess the impact of regulations and implications on safety as well as extreme process conditions and steps that should be taken to ensure proper compliance.

**Moderator:** Peter J. Makowenskyj, MEng, Director of Design Consulting, *G-CON*

15:50 – 16:15

**PUPSIT in the Revised EU GMP Annex I – Friend or Foe of the Pharmaceutical Entrepreneur?**

**Presenter:** Manuel Grund, Process Engineer, *Roche Pharmaceuticals*

16:15 – 16:40

**Contamination Control Strategies in Processing of Frozen Sterile Bulk Drug Product in Single-use Bag Assembly**

**Presenter:** Yuan-An Liu, PhD, Associate Director CMC, *BioNTech SE*

16:40 – 17:10

**Q&A, Discussion**

**Moderator:** Peter J. Makowenskyj, MEng, Director of Design Consulting, *G-CON*

**Panelist:** Manuel Grund, Process Engineer, *Roche Pharmaceuticals*

**Panelist:** Yuan-An Liu, PhD, Associate Director CMC, *BioNTech SE*

---

Session 2, Track B: Aseptic Set-Up of Filling Machines
Salon Köln, Bonn, Hamburg

With the requirements of the new EU GMP Annex 1, the aseptic set-up of a filling machine gets challenging. In former times you could use the VHP cycle as the final sterilization step. This is not possible anymore. Indirect product contact parts have to be (ideally steam-) sterilized and installed after the VHP cycle. The track shows two different approaches that are both relevant these days: One with an existing isolator line where you use enhanced “classical” methods to install the steam sterilized parts. And a completely newly developed machine with a gloveless isolator. Where you do steam sterilization for the indirect product contact parts and a fully automatic aseptic transfer and installation by using RTP ports and a robot. For the filling path, both solutions use pre-sterilized single-use filling systems.

**Moderator:** Klaus Ullherr, Senior Product Manager, *Syntegon Technology GmbH*

15:50 – 16:15

**Implementing EU GMP Annex 1 Guidelines: A Comprehensive Approach to Sterility Assurance for Indirect Product Contact Parts**

**Presenter:** Christian Rust, B.S. Chemical and Biomolecular Engineering, Technical Operations, *MSD*
Compliance with New EU GMP Annex 1 on a Fill/Finish Machine: A Glance into the Future

Presenter: Helen Sauter, Dr, Director Quality Assurance, Vetter Pharma Fertigung GmbH & Co. KG

Q&A, Discussion

Moderator: Klaus Ullherr, Senior Product Manager, Syntegon Technology GmbH
Panelist: Christian Rust, B.S. Chemical and Biomolecular Engineering, Technical Operations, MSD
Panelist: Helen Sauter, Dr, Director Quality Assurance, Vetter Pharma Fertigung GmbH & Co. KG

End of Conference Day 1 & Networking Event

Thursday, 16 May

08:00 – 17:45
Registration Open
Saal MARITIM & Lobby Empore

09:00 – 10:30
Session 3, Track A: Environmental Monitoring
Alte Stuttgarter Reithalle
This session will cover the latest developments in environmental monitoring (EM). The presenters will discuss how the data is utilized to adapt the new and updated approach for a better EM including the improvements enhanced to be compliant with Annex 1. The session will address new innovative ways to evaluate real-time continuous air monitoring. Two case studies will be presented, lessons learned from implementing total particle count tubing qualification on non-viable particle count systems and Automated Reading of Agar Plates using AI. Attendees will gain insights into the latest techniques in Environmental Monitoring, associated challenges and learnings, and how these advancements can be applied to impact our industry.

Moderator: Hue Kwon, PhD, Advisory consultant, GLS Advisors LLC

09:00 – 09:20
Total Particle Count – Tubing Qualification at GSK: Lessons Learned

Co-Presenter: Paul Devuyyst, Master Bioengineer, Senior Manager Aseptic Technologies, GSK

Co-Presenter: Kurt Jaeques, MA, Global Aseptic Technologies Lead Monitoring & Control, GSK

09:20 – 09:40
How to Collect All Environmental Monitoring Data and Doing Computerized Trending Without Entering the Data Manually
Session 3, Track B: Equipment for Aseptic Processes
Salon Köln, Bonn, Hamburg

During this session, we will explore the technological advancements that could enhance existing production lines and address specific material transfer needs to minimize particulates, pyro, and bioburden. The speakers will delve into strategies for aligning practices with the Annex requirements. We will discuss how leveraging technology can enhance aseptic environments and share insights on retrofitting equipment and processes to meet material transfer and sanitization standards. Our approach will break down these complex concepts into manageable steps that can be seamlessly integrated into your operations.

**Moderator:** Tracy Moore, Director, TM Pharma Group Ltd
### Agenda

**PDA Good Aseptic Manufacturing Conference 2024**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 – 10:30</td>
<td>Q&amp;A, Discussion</td>
</tr>
<tr>
<td></td>
<td><strong>Moderator:</strong> Tracy Moore, Director, TM Pharma Group Ltd</td>
</tr>
<tr>
<td></td>
<td><strong>Panelist:</strong> Anna Campanella, PhD, Global Aseptic Processing &amp; Sterility Assurance, Takeda Pharmaceuticals International AG</td>
</tr>
<tr>
<td></td>
<td><strong>Panelist:</strong> Johannes M. Rauschnabel, PhD, Director Advanced Technology Development and Innovation, Syntegon Technology GmbH</td>
</tr>
<tr>
<td></td>
<td><strong>Panelist:</strong> David Keen, MRSB CBIol, Director Pharmaceutical Microbiology &amp; Consulting, Ecolab Life Sciences</td>
</tr>
<tr>
<td>10:30 – 11:00</td>
<td>Networking Coffee Break, Poster Session &amp; Exhibition</td>
</tr>
<tr>
<td></td>
<td>Saal MARITIM &amp; Lobby Empore</td>
</tr>
<tr>
<td>11:00 – 12:20</td>
<td>Session 4, Track A: RABS/Isolator</td>
</tr>
<tr>
<td></td>
<td><strong>Moderator:</strong> David Keen, MRSB CBIol, Director Pharmaceutical Microbiology &amp; Consulting, Ecolab Life Sciences</td>
</tr>
<tr>
<td></td>
<td><strong>Panelist:</strong> Bianca Bohrer, Dipl Ing, Managing Director, PSM GmbH</td>
</tr>
<tr>
<td></td>
<td><strong>Panelist:</strong> Martin Novak, MSc, Technology Lead, SKAN AG</td>
</tr>
<tr>
<td>11:00 – 11:25</td>
<td>Pre-Validation of a Gloveless Isolator Filling Line - Experience and Lessons Learned</td>
</tr>
<tr>
<td></td>
<td><strong>Presenter:</strong> Bianca Bohrer, Dipl Ing, Managing Director, PSM GmbH</td>
</tr>
<tr>
<td></td>
<td><strong>Presenter:</strong> Martin Novak, MSc, Technology Lead, SKAN AG</td>
</tr>
<tr>
<td>11:50 – 12:20</td>
<td>Q&amp;A, Discussion</td>
</tr>
<tr>
<td></td>
<td><strong>Moderator:</strong> David Keen, MRSB CBIol, Director Pharmaceutical Microbiology &amp; Consulting, Ecolab Life Sciences</td>
</tr>
<tr>
<td></td>
<td><strong>Panelist:</strong> Bianca Bohrer, Dipl Ing, Managing Director, PSM GmbH</td>
</tr>
<tr>
<td></td>
<td><strong>Panelist:</strong> Martin Novak, MSc, Technology Lead, SKAN AG</td>
</tr>
</tbody>
</table>
Concerning the EU GMP Annex 1, QRM Quality Risk Management includes the Contamination Control Strategy CCS with all procedures and processes for the safe production of the sterile pharmaceutical product. An essential component of quality risk management is the ICH Q9 to identify the possible risks in the production of the sterile product and to integrate them into the contamination control strategy. In the Aseptic Process Simulation APS, the entire process is checked by all operators to ensure the sterility of the pharmaceutical drug.

**Moderator:** Richard Denk, Senior Consulting Aseptic Processing & Containment, SKAN AG

11:00 – 11:25

**A Matter of Uncertainty: Risk Tool Selection With ICH Q9(R1) In Mind**

**Presenter:** Amanda McFarland, MS, Senior Consultant, ValSource, Inc.

11:25 – 11:50

**Using Risk Management to Design Aseptic Process Simulations**

**Presenter:** Alberto Gonzalez, Global Sterility Assurance Associate Director, Takeda

11:50 – 12:20

**Q&A, Discussion**

**Moderator:** Richard Denk, Senior Consulting Aseptic Processing & Containment, SKAN AG

**Panelist:** Alberto Gonzalez, Global Sterility Assurance Associate Director, Takeda

**Panelist:** Amanda McFarland, MS, Senior Consultant, ValSource, Inc.

12:20 – 13:20

**Networking Lunch Break, Poster Session & Exhibition**

Saal MARITIM & Lobby Empore

13:20 – 13:30

**Interactive Questionnaire Session**

Alte Stuttgarter Reithalle

13:30 – 14:15

**Closing Plenary Part I**

Alte Stuttgarter Reithalle

**Moderator:** Darren Beckett, Sr. Training and R&D Manager, Fedegari Technologies Inc
13:30 – 13:40
Excitement @Syntegon – Insights and Preparation for the Syntegon Factory Tour

Presenter: Klaus Ullherr, Senior Product Manager, Syntegon Technology GmbH

13:40 – 13:55
Introduction of PDA Points to Consider (PtC) for Aseptic Filling

Presenter: Julian Petersen, Head of Business Development, groninger & co. gmbh

13:55 – 14:15
Evolution of GMPs and Why They Are Particularly Important for Sterile Manufacturing

Presenter: Andrew D. Hopkins, PGDip, Director, Operation Quality QA Audit and Compliance, AbbVie Inc.

14:15 – 14:45
Networking Coffee Break, Poster Session & Exhibition
Saal MARITIM & Lobby Empore

14:45 – 14:50
Passport Raffle
Alte Stuttgarter Reithalle

Moderator: Melanie Decker, Parenteral Drug Association

14:50 – 16:20
Closing Plenary Part II
Alte Stuttgarter Reithalle

Moderator: Darren Beckett, Sr. Training and R&D Manager, Fedegari Technologies Inc

14:50 – 15:15
A Review of Recent Inspectional Trends: Aseptic Manufacturing - remote presentation -

Regulatory Presenter: Brooke K. Higgins, MS, Branch Chief, OC, CDER, U.S. FDA

15:15 – 15:40
Updates on EU GMP Annex 1 - remote presentation -

Regulatory Presenter: Roberto Conocchia, MD, GMP Technical Lead, European Medicine Agency
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:40 – 16:20</td>
<td>Plenary Discussion</td>
<td>Moderator: Simone Biel, PhD, Senior Regulatory Consultant, <em>Merck</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderator: Darren Beckett, Sr. Training and R&amp;D Manager, <em>Fedegari Technologies Inc</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panelist: Julian Petersen, Head of Business Development, <em>groninger &amp; co. gmbh</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panelist: Andrew D. Hopkins, PGDip, Director, Operation Quality QA Audit and Compliance, <em>AbbVie Inc.</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panelist: Roberto Conocchia, MD, GMP Technical Lead, <em>European Medicine Agency</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panelist: Brooke K. Higgins, MS, Branch Chief, OC, CDER, <em>U.S. FDA</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panelist: Klaus Ullherr, Senior Product Manager, <em>Syntegon Technology GmbH</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panelist: Christina Delbo, PharmD, Consultant, <em>NA</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panelist: Daniel Mueller, PhD, Head of GMDP-Inspectorate, <em>Regierungspraesidium Tuebingen, Germany</em></td>
</tr>
<tr>
<td>16:20 – 16:30</td>
<td>Conference Summary from the Co-Chairs</td>
<td><strong>Co-Chair: Simone Biel, PhD, Senior Regulatory Consultant, <em>Merck</em></strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Co-Chair: Darren Beckett, Sr. Training and R&amp;D Manager, <em>Fedegari Technologies Inc</em></strong></td>
</tr>
<tr>
<td>16:30 – 16:35</td>
<td>Closing Remarks &amp; Farewell</td>
<td><strong>Committee Member: Falk Klar, PhD, <em>Parenteral Drug Association</em></strong></td>
</tr>
</tbody>
</table>